N-[[(3-氯-2-羟基-5-硝基苯基)氨基]硫酮甲基]苯甲酰胺 | 53501-41-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[[(3-氯-2-羟基-5-硝基苯基)氨基]硫酮甲基]苯甲酰胺
• 中文别名: N-[[（3-氯-2-羟基-5-硝基苯基）氨基]硫代甲基]苯甲酰胺
• 英文名称: PIT-1
• 英文别名: [N-((3-chloro-2-hydroxy-5-nitrophenyl)carbamothioyl)benzamide]；N-(2-hydroxy-3-chloro-5-nitrophenyl)-N'-benzoylthiourea；N-[(3-chloro-2-hydroxy-5-nitrophenyl)carbamothioyl]benzamide
• CAS: 53501-41-0
• 化学式: C₁₄H₁₀ClN₃O₄S
• 分子量: 351.77
• InChiKey: RIGXBXPAOGDDIG-UHFFFAOYSA-N

物化性质

• 密度：
  1.592
• 溶解度：
  二甲基亚砜：≥14mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Expansion and differentiation of inner ear supporting cells and methods of use thereof
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US11466252B2

  公开（公告）日：2022-10-11

  This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).

  本公开涉及扩增内耳支持细胞（如Lgr5+内耳支持细胞）和将内耳支持细胞（如Lgr5+内耳支持细胞）分化为内耳毛细胞（如阿托纳同源物1（Atoh1）+内耳毛细胞）的方法，以及内耳支持细胞和毛细胞的用途，如用于鉴定治疗听力损失和平衡损失的候选治疗化合物。此外，本文所述的方法还可用于治疗听力损失和平衡失调患者，这些患者将受益于内耳支持细胞（如Lgr5+内耳支持细胞）的增殖和分化。
• EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：EP3407901B1

  公开（公告）日：2021-07-21
• Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof
  申请人：Degterev Alexei

  公开号：US20120136033A1

  公开（公告）日：2012-05-31

  Disclosed are a new class of non-lipid small molecule inhibitors which interfere with the interaction between PIP3 and pleckstrin homology domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo. The small molecule inhibitors of the invention can be used alone or together with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or other cancer medicament to treat cancer. Small molecule inhibitors of the invention act synergistically in combination with TRAIL in treating cancer. Pharmaceutical compositions and methods for treating cancer are provided.
• Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US20190010449A1

  公开（公告）日：2019-01-10

  This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).
• PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS
  申请人：Frequency Therapeutics, Inc.

  公开号：US20220192984A1

  公开（公告）日：2022-06-23

  The present disclosure relates to pharmaceutical compositions (e.g., pre-lyophilized pharmaceutical compositions, lyophilized pharmaceutical compositions, and reconstituted solutions) comprising one or more otic therapeutic agents. The present disclosure also relates to methods of preparing the pharmaceutical compositions, and methods of using the pharmaceutical compositions for therapeutic purpose.